Skip to main content

My account

Boston Scientific accounts are for healthcare professionals only.

Create an account to access online training and education on EDUCARE, manage your customer profile, and connect with customer support and service teams.

My Boston Scientific account

Access your online applications and manage your customer profile.

Quick Links

Call customer care

Eluvia banner image

ELUVIA VS. BMS VS. DCB

SPORTS randomized controlled trial results.

SPORTS Clinical Trial Results​

SPORTS is the first investigator-sponsored, core-lab adjudicated, prospective, multi-centre, three-arm RCT comparing outcomes of DES (EluviaTM) vs. BMS (investigator choice) vs. DCB (SeQuent Please), 1:1:1, in TASC C/D lesions.1

SPORTS confirms that Eluvia is the definitive treatment for ​long complex lesions in the SFA2-11

12M Primary Patency across Eluvia Trials

The Eluvia DES has shown consistent performance of ~90% primary patency ​
at 12 months, no matter the lesion, no matter the patient. ​

The Eluvia arm in the SPORTS registry had an average lesion length of 235mm and is one of the most complex cohorts studied for the stent to date. ​

Primary endpoint: percentage diameter stenosis in lesion at 12 months1

Eluvia demonstrated statistically superior performance over BMS, whilst DCB was only non-inferior to BMS when evaluated angiographically for percent diameter stenosis and late lumen loss at 12 months.

Primary endpoint % Diameter Stenosis in Lesion

Secondary endpoint: freedom from CD-TLR at 12 months1

Eluvia also demonstrated superior patient outcomes over BMS and DCB ​as evidenced by freedom from TLR through the 12-month follow-up period.​

Secondary endpoint Freedom from CD-TLR

SPORTS randomized controlled trial details​

Eluvia DES​ (n=74)​DCB​ (n=74)​BMS​ (n=76)​p-value​
Average Diameter Stenosis in Lesion​25.3%​53.7%​60.0%​<0.0001​
Average Late Lumen Loss​0.4mm​1.1mm​2.0mm​<0.0001​
K-M Freedom from CD-TLR ​94.5%​80.7%​77.4%​0.015​
 ELUVIA N=74DCB N=74BMS N=76P-value
Average lension length235mm221mm227mm0.57
Occlusion85%70%74%0.08
Average occlusion length179mm175mm151mm0.18
Average diameter stenosis in lesion96.80%92.60%94.20%0.10
Mod-sev calcification58.10%71.70%67.10%0.36
Diabetes23%30%26%-
Renal disease8%12%3%-

Ordering and reimbursement

Get downloads for ordering information and reimbursement coding guides for our drug-eluting technologies.

Stay up to date

Receive emails about the latest drug-eluting technology news, innovations and events in your area.

 
References:
  1. Tepe G. SPORTS. TCT 2023, October 24, 2023, San Francisco, CA.​
  2. Imperial: Gray WA, Keirse K, Soga Y, et al; IMPERIAL investigators. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomized, non-inferiority trial. Lancet. 2018;27;392(10157):1541–1551. Müller-Hülsbeck S, Benko A, Soga Y, et al. Two-year efficacy and safety results from the IMPERIAL Randomized study of the Eluvia polymer-coated drug-eluting stent and the Zilver PTX polymer-free drug-coated stent. Cardiovasc Intervent Radiol. 2021;44:368–375
  3. EMINENT: Gouëffic Y, Torsello G, Zeller T, et al; EMINENT Investigators. Efficacy of a drug-eluting stent versus bare metal stents for symptomatic femoropopliteal peripheral artery disease: Primary results of the EMINENT randomized trial. Circulation. 2022;146:1564–1576.
  4. Majestic: Müller-Hülsbeck S, Charing Cross 2015. Müller-HülsbeckS, et al. Cardiovasc Intervent Radiol. 2017;40(12):1832–1838.
  5. Regal: Lansik W. Real world all comers data from the REGAL registry – 2-year results. Presented at LINC 2023.
  6. Auckland: Holden, A. Single Centre Long-Term Experience with the Boston Scientific Eluvia DES in Femoro-popliteal Artery Occlusive Disease. LINC 2020.
  7. IMPERIAL Long: Müller-Hülsbeck S, Benko A, Soga Y, et al. Two-Year Efficacy and Safety Results from the IMPERIAL Randomized Study of the Eluvia Polymer-Coated Drug-Eluting Stent and the Zilver PTX Polymer-free Drug-Coated Stent. Cardiovasc Intervent Radiol. 2021;44(3):368–375. 
  8. Capsicum: Iida O, Takahara M, Soga Y, et al; CAPSICUM Investigators. 1-Year Outcomes of Fluoropolymer-Based Drug-Eluting Stent in Femoropopliteal Practice: Predictors of Restenosis and Aneurysmal Degeneration. JACC Cardiovasc Interv. 2022 Mar 28;15(6):630–638. Iida LINC 2023.
  9. Desafinado: Kum S, Ipema J, Huizing E, et al. Outcomes of the paclitaxel-eluting Eluvia stent for long femoropopliteal lesions in Asian patients with predominantly chronic limb-threatening ischemia. Vasc Med. 2021;26(3):267–272.
  10. Muenster: Stavroulakis K, Torsello G, Bosiers M. 2-Year Outcomes of the Eluvia Drug-Eluting Stent for the Treatment of Complex Femoropopliteal Lesions. JACC Cardiovasc Interv. 2021;14(6):692–701.
  11. Ultimate: Ichihashi S, Takahara M, Yamaoka T, et al. Drug eluting versus covered stent for femoropopliteal artery lesions: Results of the ultimate study. Eur J Vasc Endovasc Surg. 2022;64(4);359–366

Caution:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.